MedTrace Logo

The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy

NCT04782622 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-03-04

No results posted yet for this study

Summary

The combination of Apatinib and Camrelizumab for progressed NSCLC patients with muti-line therapy : a phaseⅠB clinical study.

Brief Summary: Immunotherapy has made a major progress in Lung cancer.However, challenges such as primary and acquired resistance, small fraction of benefit population and lack of predictive and prognostic biomarkers even exist. The overall objective response rate is lower than 20% in second line-treatment and the progression-free survival (PFS) is also similar to or poorer than that of conventional second-line chemotherapy. Apatinib is a novel, orally administered, multitarget receptor tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FGFR, c-Kit, and other kinases. It functions by inhibiting tumor angiogenesis and proliferative signaling pathways. We would observe and analyze the effectiveness and safety of apatinib combined with Camrelizumab for advanced NSCLC after muti-line therapy to explore the synergistic effect of anti-angiogenic agents and immunotherapy.

Conditions

Interventions

DRUG

Apatinib+Camrelizumab

Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d

Sponsors & Collaborators

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-01-01
Completion
2023-03-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04782622 on ClinicalTrials.gov